Persistent infection with hepatitis B virus (HBV) is one of the primary risk factors for human hepatocellular carcinoma (HCC). In a human ecological study, we have shown that, in addition to HBV, animal food consumption also signi®cantly contributes to the variance of HCC. To test the interacting eect of HBV and animal food consumption on the development of HCC, we investigated HBV expression in HBV transgenic mice fed three levels of casein diet. HBV expression in transgenic animals was substantially inhibited when dietary casein was reduced from the traditional level of 22% to the level of 6%. Northern analysis revealed that suppression of HBV was derived from both the upstream albumin promoter and the internal HBV promoter. Immunochemical staining of liver sections indicated that only a few hepatocytes around the central vein expressed viral surface antigen (HBsAg) in the 6% casein animals, whereas virtually all hepatocytes stained positively for HBsAg in the 22% dietary casein animals. Serum HBsAg concentrations at 4 months were increased by 1.6-, 2.1-, and 5.1-fold over baseline for animals fed the 6%, 14%, and 22% casein diets, respectively. Correspondingly, liver injury was much less severe in animals fed 6% casein diet than in those fed 14% and 22% casein diets. These results demonstrate that a low casein diet is a potent suppresser of HBV transgene and HBVinduced liver injury, suggesting that diet management may be a practical means to aid in the control HBV infection.
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Introduction
Human hepatocellular carcinoma (HCC) is one of the most prevalent cancers in Southern Africa and eastern Asia (Di Bisceglie et al., 1988; Parkin et al., 1988; Vatanasapt et al., 1995) , ranking in the top four causes of cancer death in China. The geographical distribution of this malignant disease has been etiologically linked to several environmental factors, including chronic infection with hepatitis B virus (HBV) (Beasley et al., 1981; Campbell et al., 1990; Di Bisceglie and Hoofnagle, 1987; Lutwick, 1979; Szmuness, 1978) , a¯atoxin B1 (AFB1) intake (International Agency for Research on Cancer, 1987) , excess alcohol consumption (International Agency for Research on Cancer, 1988) , cigarette smoking (Tanaka et al., 1995; Yu et al., 1991) , and nutritional factors (Campbell et al., 1990) .
Epidemiological evidence has strongly associated chronic HBV infection with the development of HCC (Beasley et al., 1981; Campbell et al., 1990; London, 1981; Lutwick, 1979) . HBV infects more than 250 million victims worldwide, accounting for an average of 10 ± 20 fold (Bosch and Munoz, 1988) or even up to 200 ± fold (Beasley et al., 1981) increased risk of HCC as compared with individuals who are HBV noncarriers. Geographical variations in the prevalence of HCC are in general agreement with the distribution of HBV infection (London, 1981) . The relationship between HBV viral infection and human HCC has been extensively reviewed elsewhere (see recent reviews (Robinson, 1994; Popper et al., 1987; Sallie and M, 1994; Kew, 1996) for detail information).
Although it is now widely accepted that HBV infection is closely associated with human HCC, uncertainty still exists as to the exact pathogenetic mechanisms involved. Experiments with HBV-transgenic mice have indicated that the sub-genomic DNA of HBV can function as a complete hepatic carcinogen. Mice carrying the HBV transgene develop, in sequence, hepatocellular injury, regenerative hyperplasia, nodules and ®nally HCC (Chisari et al., 1986; . In cell transfection studies, one of the viral proteins, HBX protein, is a potent transactivator of many cellular genes, including the protooncogenes, c-myc (Balsano et al., 1991) and ras (Doria et al., 1995) . Introducing the HBV DNA encoding this viral transactivator into the mouse genome also produced HCC in transgenic animals (Kim et al., 1991) .
There is mounting evidence that HBV DNA is frequently integrated into cellular DNA of HCC tissues (Chang et al., 1991; Rogler et al., 1985; Tanaka et al., 1986; Yaginuma et al., 1987) . The integration sites of HBV often contain multiple chromosomal rearrangements, including deletions, inversions, and insertions. Examination of the molecular mechanism of HBVinduced hepatocarcinogenesis has been hampered by the fact that no consensus viral DNA integration sites have been observed (Yaginuma et al., 1987) , nor has HBV integration been demonstrated to be adjacent to known cellular proto-oncogenes that are related to HCC.
In a comprehensive diet, lifestyle and disease mortality study of 48 counties of rural China (Campbell et al., 1990) , it was observed that the principal correlates of HCC were persistent infection with HBV, alcoholic beverage consumption, and nutritional factors which elevate plasma cholesterol. These results suggested that human HCC is primarily initiated by persistent infection with HBV, and perhaps other environmental hepatic carcinogens, followed by promotion with nutritional factors that can modulate neoplastic cell growth. To test this hypothesis, we investigated the modulating eect of dietary casein on expression of HBV and on liver injury in HBVtransgenic mice, an accepted model for the development of human HCC (Chisari et al., 1989) .
Results

Expression of HBV-transgene
Expression of the HBV transgene was examined at the mRNA level in transgenic mice fed three levels of casein diet. We ®rst used PCR to quantitate HBV expression with primers made speci®cally for the HBV transgene ( Figure 1 ). As expected, the HBV-transgene RNA was not detectable in the non-transgenic normal controls. In transgenic mice fed the 22% casein diet, there was substantial expression of HBV-trasngene, as previously reported (Chisari et al., 1985 (Chisari et al., , 1986 . In mice fed the 6% casein diet, however, a dramatic decrease in the expression of HBV transgene was observed. There was a clear dose-response relation between dietary casein intake and HBV-transgene expression in these transgenic mice.
In addition to the albumin promoter that was located upstream of the HBV transgenic DNA in the vector (Chisari et al, 1985 (Chisari et al, , 1986 , there is a second internal HBV S-promoter in the HBV transgenic DNA insert. This internal HBV S-promoter, derived from the original HBV genome, also drove the expression of HBV RNA in transgenic mice although it did not contain the in-phase translation site for the large envelope polypeptide antigen (Chisari et al., 1986) . To determine whether the increased HBV expression was derived from the external albumin promoter or from the internal HBV S-promoter, Northern blotting was used to quantitate the HBV expression in the same transgenic mice. The external albumin promoter drove HBV expression, yielding a 2.6 kb RNA, while the internal HBV S-promoter expressed a 2.1 kb HBV RNA. Interestingly, as seen in Figure 2 , expression of HBV from both external and internal HBV Spromoters were activated in mice fed the high 22% casein diet, but blocked in animals fed the low 6% casein diet.
The inhibiting eect of low casein diet on HBVtransgene was also examined at the protein level by immunohistochemical staining of liver sections. Mice were selected from each treatment group after 3 months of feeding (two from control, 6%, and 14% casein groups, respectively, and three from 22% casein group). Liver sections were stained immunohistologically with polyclonal antibody raised against the HBV surface antigen ( Figure 3 ). As previously reported (Chisari et al., 1985 (Chisari et al., , 1986 , virtually all hepatocytes were immuno-stained positively for HBsAg protein in mice fed the high casein diet (22%), indicating that the HBV transgene was highly expressed in these mice. In mice fed the low casein diet (6%), however, only a few hepatocytes around the central vein were shown to express HBV-transgene, while the majority of hepatocytes in this section did not stain for the surface antigen. Combined with the results from the mRNA analysis (Figures 1 and 2 ), these data indicate that the expression of the HBV transgene was substantially suppressed in mice fed the low casein diet.
After 3 months of diet treatment, the increase in serum HBsAg that was usually observed among transgenic animals (Chisari et al., 1987) , was markedly suppressed in the animals fed the 6% casein diet (1.6 fold increase) compared to the animals fed the 14% Figure 1 were hybridized with an HBV probe labeled with 32 P-adCTP. The external albumin promoter (pAlb) transcribes a 2.6 kb mRNA while the internal HBV S-promoter (PInt) drives HBV expression, giving 2.1 kb HBV transcripts casein diet (2.1 fold increase) and the 22% casein diet (5.1 fold increase) (Figure 4) . However, after 6 months of diet treatment, some of these dierences had begun to attenuate, showing increases from baseline of 4.2-, 5.6-and 6.1-fold, respectively, for the 6%, 14%, and 22% dietary casein fed animals.
HBV-induced liver injury
Serum GPT levels are commonly used clinically as an indication of liver damage. As previously reported (Chisari et al., 1987) , HBV-transgenic mice had substantially higher levels of serum GPT as compared with non-transgenic normal mice (data not shown). After diet treatment, the pattern of serum GPT in these transgenic mice changed dramatically (Figure 4) . Serum GPT levels gradually declined, (though not in a statistically signi®cant amount from the baseline values), in mice fed the 6% casein. In contrast, after 3 and 6 months on diet, mice fed the high casein group (22%) exhibited a substantially greater increase in serum GPT than mice fed 6% casein diet (P50.05). These results suggest that feeding mice the low casein diet leads to much less long-term liver damage.
We also measured serum GPT for HBV nontransgenic mice, which were raised in parallel with transgenic mice as an experimental control. No signi®cant dierences in serum GPT were found between low (6%) and high (22%) casein animals (74.0 mg/L vs 76.6 mg/L after 3 months of experiment)(data not shown), indicating that a low casein diet, which is at the level of minimum body requirement, does not aect serum GPT levels. These results thus suggest that reduction in GPT values observed in HBV transgenic mice fed 6% casein diet was associated primarily with low HBV expression in transgenic animals.
Expression of growth factors
As a ®rst step to explore the underlying mechanism for the suppressive eect of low casein diet on HBV expression, we examined several growth factors that may be involved in hepatocarcinogenesis (Pasquinelli et al., 1994) (Figure 5 ). HGF and IGF1 mRNA abundance was not signi®cantly dierent in mice fed dierent casein diets. However, mice fed the high casein diet showed greater expression of IGF2 mRNA than non-transgenic mice and transgenic mice fed the low casein diet. There was a signi®cant correlation between the HBV transgene expression and IGF2 expression in these transgenic mice.
Discussion
The HBV transgene contains three in-phase translation start codons and a shared termination signal (Chisari et al., 1985 (Chisari et al., , 1986 Figure 3 Immunohistochemical staining of HBS protein in the liver of normal (top left panel) and HBV transgenic mice fed 6%, 14% and 22% casein diets (top right, bottom left and right panel, respectively), 1006. Livers were collected at month 3 following diet treatment, and were immuno-stained with antiserum to HBsAg (Chisari et al., 1986 (Chisari et al., , 1987 encodes the major envelope polypeptide, which is the dominant structural component of the HBV surface antigen particle (HBsAg). Circulating HBsAg antigen can be readily detected and measured as a reliable indicator of hepatic viral infection. In the present study, we found that HBV-transgenic mice fed a normal protein diet (22% casein) expressed HBV transgene products at a high level as previously reported (Chisari et al., 1986) , beginning as early as weaning (Figure 4 ). Hepatic export of HBsAg antigen in these mice continued to increase to high levels when mice were fed intermediate or high casein diets. However, when fed the low casein diet, transgenic mice secreted much less HBsAg into the circulation.
It was suggested that liver damage caused by HBV infection was derived from the imbalanced production of the large and major polypeptides (Chisari et al., 1987) . The large polypeptide, which is not readily secreted into the blood, becomes entrapped within the cell and blocks the secretion of the major polypeptide. We wondered whether a similar mechanism might account for the reduced serum levels of HBsAg in the transgenic mice fed the low casein diet. As seen in Figure 3 , virtually all hepatocytes in mice fed the 6% casein diet, except for several cells around the central vein, failed to express the HBsAg antigen. In contrast, the entire liver sections of the animals fed the 14% and 22% casein diets stained positively for the HBV product. These results indicate that low levels of serum HBsAg in mice fed 6% casein diet resulted from the reduced expression of HBV and not from the entrapped major polypeptide (Chisari et al., 1987) . This ®nding has been further con®rmed by PCR and Northern quantitation of HBV-mRNA transcripts (Figures 1 and 2 ). The HBV transgene was transcribed at high levels in the transgenic mice fed 22% dietary casein but were depressed by about 85% in the animals fed 6% dietary casein.
The mechanism(s) for the reduced mRNA expression of HBV transgene by a low casein diet is still unknown. Some liver-speci®c proteins, like albumin, are known to respond to dietary management, such as diet restriction or protein malnutrition, by reducing hepatic protein synthesis. Because the HBV transgene contains the albumin promoter, which is located upstream of the inserted HBV DNA, we ®rst suspected that the reduced expression of HBV transgene in the animals fed the 6% casein diet might be related to the low expression of the albumin promoter. To test this hypothesis, we used Northern hybridization to examine the HBV transgene transcripts. With Northern blotting, the origin of the HBV transcripts, whether from the albumin promoter or from the internal HBV S-promoter, can be distinguished. The upstream albumin promoter drives HBV expression to produce a 2.6 kb mRNA, while the internal HBV S-promoter expresses a 2.1 kb mRNA. If the albumin promoter hypothesis is true, suppression of HBV in low casein animals should be due to the selective decrease in the 2.6 kb mRNA that is derived from the albumin promoter, while the 2.1 kb mRNA, which is from the HBV internal promoter, should remain unchanged. However, as shown in Figure 2 , mRNAs from both the albumin promoter and the internal HBV S-promoter were altered in a similar fashion among three treatment groups. These results thus exclude the possibility that the low expression of HBV in the 6% casein diet group was due solely to the inactivation of the albumin promoter after the diet treatment.
Calorie consumption is not a confounding factor accounting for repression of HBV in the low casein animals. First, calorie intake was not restricted in these transgenic animals. Although three experimental diets contain dierent levels of casein (6%, 14% and 22%), they were made isocaloric in order to reduce the interference of calorie eect. Second, we measured food consumption and body weight for HBV transgenic mice. Interestingly, as previously reported (Youngman and Campbell, 1992b) , animals in the low protein group consumed more food, and thus more calories than animals in the high protein group (Cheng et al, unpublished data). Thus, it is the low casein in the diet, rather than the calorie intake, that acts as a potent repressor of HBV expression in transgenic mice.
Dietary casein, as nutrient, can not directly act on HBV transcription. We hypothesized that there may be some`nutrient-responding factors' to mediate this suppressing eect. The role of growth factors in the development of viral-induced in¯ammation and tumorigenesis has recently attracted much attention. Hepatocyte growth factor (HGF), a potent mitogen for primary cultures of hepatocytes in vitro, is highly expressed in early regenerative stages following partial hepatectomy (Kinoshita et al., 1991; Zarnegar et al., 1991) . Insulin-like growth factor I (IGF1), which is frequently overexpressed in many tumors (Sussenbach , 1992) , has been shown to be markedly reduced by feeding low protein diets (Clemmons and Underwood, 1991; Maiter et al., 1988; Straus and Takemoto, 1990) . However, both HGF and IGF1 mRNA levels remained unaected in these HBV-transgenic mice fed dierent casein diets ( Figure 5 ). Therefore, these two growth factors, although thought to be important in the development of hepatic malignancies in other models (Antoniades et al., 1992; Arteaga et al., 1989; Maier et al., 1996) , may not be signi®cantly involved in the viral pathogenesis in these transgenic mice. Insulin-like growth factor II (IGF2), an essential embryonic growth factor (DeChiara et al., 1990) , is overexpressed in many human malignancies. In woodchuck hepatocellular carcinoma, expression of IGF2 increased in parallel with that of hepatitis virus DNA expression and the formation of liver tumors (Schirmacher et al., 1992; Yang and Rogler, 1991) . In the present study, we also found a similar expression pattern of IGF2 and HBV-transgene mRNA in mice fed three levels of dietary casein (Figures 1 and 5) . These results suggest that IGF2 may act in coordination with the HBV transgene in causing hepatocyte proliferation and transformation. However, the speci®c mechanisms for the interaction between diet, HBV, and IGF2 in HBV-induced hepatocarcinogenesis await further investigation.
HBV expression was positively correlated with liver damage and subsequent tumor development (Chisari et al., 1989) . In this study, we found that animals fed a low casein diet expressed the HBV transgene at very low level (Figures 1 and 3) . Consequently, the liver damage caused by HBV overexpression was also substantially reduced as indicated by the low levels of serum GPT (Figure 4) . In those transgenic mice fed 14% and 22% casein diets, in contrast, serum GPT continued to increase to high levels. The causal eect of HBV transgene overexpression on liver injury also can be seen from the positive correlation between serum HBsAg and GPT levels (data not shown). These results thus suggest that lowering dietary protein may provide a feasible means to control liver damage caused by HBV overexpression.
We have previously reported that feeding a low casein diet or plant protein diet signi®cantly reduced preneoplastic lesions and hepatic tumors in rats when AFB1 was used as a carcinogen (Youngman and Campbell, 1992a,b) . In a recent study using another HBV X protein transgenic mice (Kim et al., 1991) , we also found that the formation of HBX-induced hepatoma was substantially reduced in transgenic mice fed the low casein diet as compared with that fed the high casein diet (Cheng, et al. unpublished data) . Taken together, these ®ndings suggest that a low protein diet, or plant protein, may be bene®cial for HBV carriers, particularly considering the ultimate consequence of HCC in these high risk populations. Dietary management, especially through manipulation of dietary protein, may provide a practical and important way to control chronic infection with HBV and liver damage, as demonstrated both by reduced expression of HBV and low serum GPT in animals fed a low casein diet. If this hypothesis also holds true for humans, it would be prudent to recommend that HBV chronic carriers consume a low protein or plant protein diet, instead of a high animal protein diet as is clinically recommended in China. Further studies, such as epidemiological surveys or clinical invention trials, are needed to con®rm these animal ®ndings.
Materials and methods
Transgenic mice
Four 50-4 HBV-transgenic males, prepared as previously described (Chisari et al., 1985 (Chisari et al., , 1987 , were mated with normal C3H females purchased from the Jackson Laboratory (Bar Harbor, Maine). The HBV-transgene, which drives expression of the HBV large, middle and small envelope proteins in these animals, was transmitted to the ospring in a normal Mendelian pattern, such that half of the newborn mice are HBV-positive (Chisari et al., 1985) . At the time of weaning, whole blood samples were collected by retro-orbital plexus phlebotomy and were screened for the presence of HBV surface antigen (HBsAg). The HBV-positive mice were randomly assigned to three treatment groups, receiving 6%, 14%, and 22% casein diets, respectively. These three diets, made isocaloric by adding a mixture of cellulose : corn starch : sucrose (0.5 : 1.5 : 5.0), have been routinely used in this laboratory to study the eects of dietary protein on AFB1-induced hepatocarcinogenesis in Fischer 344 rats (Youngman and Campbell, 1992b) . The HBV-negative mice were used as normal controls in the study.
RNA analysis
Mice were sacri®ced at the third month of the experiment (4 month of age). Livers were harvested and total RNA was extracted with RNAzol B solution (Cinna/Biotecx Laboratories, Inc., Houston, TX). Messenger RNA abundance was assessed by PCR ampli®cation of liver cDNA samples that were synthesized with RNA reverse transcriptase (Hu et al., 1995; Vu and Homan, 1994) .
For the PCR reaction, the cDNA samples were ampli®ed in a 2.5 ml mixture in the presence of 50 mM dNTP, 0.2 mM primers, 0.25 mCi a-dCTP (Amersham Co., Arlington Heights, IL), 0.125 U T¯DNA polymerase (Epicentre Technologies, Madison, WI) with a hot-start PCR (Hu et al., 1995 (Hu et al., , 1996 Vu and Homan, 1994) . The cDNAs and primers were heated to 958C for 2 min, then ampli®ed for 28 cycles at 948C for 40 s, 658C for 1 min, followed by a 5 min extension at 728C. After PCR, the ampli®ed DNAs were electrophoresed on 5% polyacrylamide-urea gel and were exposed to the screen of a Phosphoimage Scanner (Molecular Dynamics, Sunnyvale, CA). After Phosphoimage scanning, the image density was calculated and compared to the density of an internal b-actin PCR control (Hu et al., 1995 (Hu et al., , 1996 . Under these PCR conditions, PCR signals were shown to be linear over a wide range of cDNA templates (Hu et al., 1996) .
The oligonucleotide primers used for PCR quantitation include: (1) Both HBS (HBV surface antigen) and HBX (HBV Xprotein) primers were used to amplify dierent parts of the HBV mRNA transcripts.
Northern blotting
Total liver RNA (15 mg) was electrophoresed on 1.5% agarose gel and transferred to Hydrobond ®lter (Amersham Co., Arlington Heights, IL). The ®lter was prehybridized with 50% formamide, 56SSPE, 26Denhardt's reagent, 0.1% SDS and 100 mg/dL speared sperm DNA, at 428C for 2 h and then was hybridized with HBV probe. The hybridization probe, a 3.2 kb tandem insert of HBV DNA (Chisari et al., 1986) , was labeled by the random primer method (Gibco BRL, Gaithersburg, MD) in the presence of 32 P a-dCTP (Amersham Co., Arlington Heights, IL). The ®lter was washed and exposed to the screen of Phosphoimage Scanner (Molecular Dynamics, Sunnyvale, CA) for quantitation. For the quantitation of the internal control (18S RNA), the same ®lter was stripped and rehybridized with a 140 bp a-dCTP-labeled probe, which was synthesized by PCR using the same reaction conditions as above for HBV quantitation, except that only 25 cycles were used. The 18S PCR primers used for making probe were: 5'-primer ATCCTGCCAGTAG-CATATGCTTGTCT and 3'-primer TTATCCAAGTAG-GAGAGGAGCGAGC.
Immunohistochemical staining for HBV
HBV expression was also examined by immunohistological staining in liver sections. Liver tissue samples were collected after 3 months of diet treatment, ®xed in 10% neutral buered formalin solution, embedded in paran, and sectioned for immunohistochemical staining of HBsAg (Chisari et al., 1987; Chisari et al., 1986) . Sections were incubated with goat polyclonal anti-HBsAg (1 : 500 dilution, Dako Corp., Carpinteria, CA). After washing with phosphate-buered saline (PBS), the sections were incubated with biotinylated anti-goat serum (1 : 500 dilution, Dako Corp., Carpinteria, CA), and stained by ABC kit (Victor Laboratories, Burlingame, CA), using Victor VIP as substrate. The sections were lightly counter stained with hemotoxalin for histological examination.
Serum HBsAg
Serum HBsAg is the HBV gene product that is produced in the infected hepatocytes and secreted into circulation. Blood samples were collected from the retro-orbital vein at baseline (age of 1 month), and then at 3 and 6 months after the onset of diet treatment (age of 4 and 7 months). One portion of the whole blood sample (20 ± 50 ml) was assessed for HBsAg levels (HBS gene product) using an HBsAg detection kit (Abbott Laboratories, Chicago), according to the manufacturer's instructions. The spectrophotometric readings were calibrated against the HBsAg standard curve and were adjusted for volume of blood sample tested.
Liver injury
Serum alanine aminotransferase (GPT) was used to estimate the degree of liver injury induced by HBV overexpression. Serum samples, collected from the experimental mice at the baseline, 3 months and 6 months after diet treatment, were assessed for GPT with the Sigma diagnostic kits (DG159-K) according to the manual of the manufacturer.
